NCT06950086View on ClinicalTrials.gov

Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

January 2, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

November 30, 2026

Conditions
HR-positive, HER2-negative Advanced Breast Cancer
Interventions
DRUG

TYK-00540

Increased dose cohorts from low to MTD (5mg Cohort 1;10 mg Cohort 2; 20 mg Cohort 3; 30 mg Cohort 4;40 mg Cohort 5) decreased dose cohorts for the combination (TYK-00540 30 mg+Fulvestrant Cohort 1;TYK-00540 20mg +Fulvestrant)

Trial Locations (2)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

TYK Medicines, Inc

INDUSTRY